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It is well established that B cell proliferation and differentiation are under the 
influence  of various  growth  factors (reviewed  in  1).  In  particular,  in  a "non- 
antigen-specific system, a  low dose of anti-IgM antibody is required to stimulate 
resting B  cells to respond  to B  cell growth  factor (BCGF), which was  recently 
named B cell stimulatory factor (BSF) (2). Various models describing these events 
postulate that activated B  cells express receptors for BSF. This is analogous to 
the expression of the interleukin 2 (IL-2) receptor by activated T  cells (3). 
Recently (4-7), a  series of new antigens preferentially expressed by activated 
human  B  cells  has  been  described.  These  have  been  named  B  blast-specific 
antigens.  None  of  these  antigens  have  been  shown  to  be  related  to  B  cell 
proliferation. In the present investigation, we identify a  new antigen expressed 
by activated human B cells by using a monocional antibody (AB1) that inhibited 
growth factor-dependent B cell proliferation. 
Materials and Methods 
Cell Preparation.  Lymphocytes were isolated from tonsils removed from patients for 
chronic tonsillitis  or from leukocyte concentrates of normal donors. B lymphocytes were 
obtained after two cycles of sheep red blood cell (SRBC) rosette depletion and adherent 
cell depletion. The tonsillar B cell preparations contained >90-95% membrane Ig (mIg)  ÷ 
cells; peripheral blood B cell preparations contained 60-80% mIg  ÷ cells. SRBC-rosetting 
lymphocytes were used as T  cells. 
Monoclonal Antibody (mAb) Production.  CF~  female mice were immunized with non- 
SRBC-rosetting cells from peripheral blood lymphocytes that had been previously acti- 
vated with pokeweed mitogen (PWM) for 3 d. The spleen cells were fused with SP2/0 
myeloma cells and hybrids were selected on hypoxanthine, aminopterin, thymidine (HAT) 
selection medium. Hybridoma supernatants were screened for their inhibition activity in 
the B cell proliferation assay as described below; they were also screened for their binding 
activity to activated B cells. The desired hybridomas were cloned on soft agar. Details of 
these procedures have been described (8). 
Lymphocyte Proliferation Assays.  10 ~ lymphocytes were stimulated  in microtiter wells 
with phytohemagglutinin (PHA-P; Difco Laboratories, Inc., Detroit, MI), PWM, concan- 
avalin A (Con A) (Gibco Laboratories, Grand Island, NY), and formalinized Staphylococcus 
aureus (a gift of Dr. S. Pahwa, Northshore Hospital, Manhasset, NY) at optimal concen- 
trations for 3  d  at  37°C  in a  humidified atmosphere containing 5%  CO2.  0.5 #Ci of 
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tritiated thymidine was added for the last 6-8 h of incubation. The amount of radioactive 
thymidine incorporated was measured after the cells were harvested onto glass filter discs 
with a scintillation counter (Beckman Instruments, Inc., Fullerton, CA). Triplicate samples 
were counted. Variations of <10% were found. 
The B cell proliferation assay was performed using affinity-purified rabbit anti-human 
IgM as a  first stimulant at a  final concentration of 5-50 t~g/ml.  Conditioned medium 
containing B cell stimulation factor (CM-BSF), produced as previously described (9), was 
added at the initiation of culture to 105 B cells per microtiter well at a final concentration 
of 10%. Supernatants of hybridomas to be screened for inhibitory activity were also added 
at the initiation of culture at a final concentration of 25%. After 3 d of culture, the cells 
were labeled with tritiated thymidine and radioactivity counted as described above. 
Immunofluorescence.  Cells were incubated with mAb for 30 min at 4°C, followed by 
incubation with a fluorescent goat anti-mouse Ig produced in our laboratory. Fluorescent 
staining  was  analyzed  using  an  EPICS  V  flow  fluorocytometer (Coulter  Electronics, 
Hialeah, FL). Integrated fluorescence of the gated population was measured and 5,000- 
10,000 cells were analyzed. 
Results 
Selective  Staining  of Activated  B  Cells  by  mAb  AB1.  Several  supernatants  of 
hybridomas generated by fusions between SP2/0 tumor cells and spleen cells of 
mice immunized  with  activated  human  B  cells isolated  from  PWM-stimulated 
peripheral mononuclear cells were found to inhibit anti-IgM-stimulated,  BSF- 
dependent B cell proliferation. One of these was shown to be specific for B cells 
activated by anti-IgM antibodies and CM-BSF. The hybridoma has been cloned 
twice and the supernatants  of the clones had similar specificity. The mAb is an 
IgG1  antibody and is termed AB1. 
The cellular distribution of AB1 antigen was studied (Table I). In six separate 
experiments with different tonsillar and peripheral blood preparations,  10-60% 
of the  activated  B  cells  stimulated  by anti-IgM  antibodies  and  CM-BSF  were 
stained by AB 1. Although there was variation between experiments, the majority 
of experiments showed >30%  of the blasts to be positive. In contrast, AB1  did 
not  stain  activated  T  cells  generated  by  PHA  stimulation.  AB1  did  not  stain 
TABLE  I 
Selective Expression of AB1 Antigen  on Activated B Cells 
Cell types  Percent 
Normal  Activated B* (four tonsils and two PBL*)  10-ri0 
Activated T  (3)  <1 
Unstimulated B (6)  <1 
Unstimulated T  (3)  <1 
Monocytes (6)  <1 
Granulocytes (6)  < 1 
Bone marrow (2)  <1 
Leukemias 
Cell lines 
B-CLL (7)  <1 
T-CLL (2)  <1 
ALL (3)  <1 
AML (2)  <1 
AMML (1)  <1 
B lymphoblastoid (20)  <1 
T  leukemia (4)  <1 
Nonlymphoid (6)  < 1 
* B cells were activated by anti-IgM antibodies and CM-BSF. 
* Number of individuals studied. JUNG AND  FU 
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FIGURE  1. 
activated by anti-lgM and CM-BSF.  ( 
antibody AB 1. 
Cytofluorometrlc  anal),sis of AB1 antigen expression by human tonsillar B cells 
) Staining with control antibody, (---) staining with 
resting B cells, T  cells, granulocytes, or monocytes. Isolated tonsillar B cells also 
showed no reactivity. AB1  did not stain bone marrow cells; cells from patients 
with chronic lymphocytic leukemia, acute lymphocytic leukemia, and nonlym- 
phoid leukemia; or cell lines of T, B, and myeloid cell origins. 
The expression of antigen AB1 did not depend on the presence of CM-BSF. 
In three separate experiments, anti-IgM antibodies (200 pg/ml) alone induced 
the expression of AB1 by 40-60% of the tonsillar B cells within 24 h. 
Kinetics of Antigen  AB1 Expression.  The kinetics of antigen AB1  was studied 
(Fig.  1). A  significant number of B cells expressed AB1  after 3 h  of incubation 
(Fig.  1B). Although the staining was not bright, this was the earliest time point 
of our experiment. By 12 h, brightly stained cells were easily detectable. 60% of 
the activated B cells were positive by 38 h. 
Inhibition of  CM-BSF-dependent Proliferation of  B Cells by AB1.  The supernatant 
of hybridoma AB I was consistently shown to inhibit B cell proliferation induced 
by anti-IgM antibodies and CM-BSF in repeated experiments. In three of these 
experiments (Table II), the inhibition was 75-98%. Anti-IgM antibodies in high 
doses and formalinized Staphylococcus aureus have been shown (10, 11) to induce 
B  cell  proliferation  without  T  cells  or  exogenous  factors.  AB1  showed  no 
inhibitory effect in  these two  growth  factor-independent B  cell proliferation 
systems. In addition, AB1  did not inhibit T  cell proliferation induced by PHA, 
Con A or PWM. In an IL-2-induced T  blast proliferation system, AB1 also had 
no effect. This selective inhibitory effect on B cell proliferation induced by anti-' 
IgM  antibodies and  CM-BSF  was similarly observed with an  IgG preparation 
isolated  from ascitic fluid  induced by hybridoma AB1.  Table  III  shows that 
isolated IgG was inhibitory in this system in a dose-dependent manner. With 25 ~ 
t~g/ml IgG (AB 1), there was no inhibitory effect on T  cell proliferation induced 
by PHA, Con A, or PWM. A partially purified BSF (12) that was devoid of IL-2 
activity was kindly provided by Drs. A. Maizel and J. Morgan (M. D. Anderson 1922  JUNG  AND  FU  BRIEF  DEFINITIVE REPORT 
TABLE  II 
AB I  Selectively Inhibits Human B Cell Proliferation Induced by a Low Dose 
of Anti-IgM Antibodies and CM-BSF 
Cell population  Stimulating agent  Exp. 
Thymidine incorporation 
Control  ABI*  medium 
Tonsilar B cells  Anti-lgM (  5 ug/ml) 
+  10% CM-BSF 
T cells 
PHA-stimulated  T 
blasts 
Cpm 
A  20,332  490 
B  12,276  2,661 
C  27,038  7,743 
Anti-igM  5 ug/ml  982  806 
25 ~/ml  4,659  4,550 
50 ug/ml  7,207  7,558 
Formalinized  A  31,486  39,330 
S. aureus (0.005%  B  66,851  57,442 
vol/vol) 
PHA (10 ug/ml)  A  31,857  37,997 
B  125,885  117,741 
C  38,641  29,147 
Con A (5 #g/ml)  52,232  53,095 
PWM(1%)  47,695  46,246 
IL-2  19,659  23,997 
10  s cells were cultured with the stimulating  agents  in microtiters  for 3 d with/without 
ABI. 0.5 taCi [SH]thymidine was added for the last 6-12 h of culture before harvesting, 
and thymidine incorporation determine  d on a Beckman scintillation counter. All cultures 
without stimulating  agents had < 1,000 cpm. Data represent means of triplicate wells. 
* Supernatant of antibody  AB 1. 
TABLE III 
Effect of aB l  on B Cell Proliferation  Induced  by anti-Igm and CM-BSF 
mAb 
Amount of antibody (tag/ml): 
0  0.5  5  10  25  50 
Control Ab*  14,747  16,137  12,679  16,968  16,262  12,171 
AB1  --  15,563  11,080  9,224  5,596  1,153 
106/ml tonsBlar B cells were stimulated  with  10 ug/ml anti-lgM  and  10% CM-BSF for 3 
d. mAb purified  on goat anti-mouse  lg affinity columns were added  at the initiation of the 
culture at the indicated concentrations. 
* IgG1 mAb. 
Hospital, Houston, TX). AB 1 in supernatant and isolated IgG forms inhibited B 
cell proliferation induced by anti-IgM antibodies and this purified BSF. 
Discussion 
In the present investigation,  mAb AB1  has been shown to detect an antigen 
expressed selectively by activated human B cells. The expression of this antigen 
was not dependent on the presence of growth factors. Anti-IgM antibodies (200 
~g/ml) by themselves were found to activate B cells to express AB1.  It remains 
to be determined if lower doses of anti-IgM  antibodies and other stimuli, such 
as formalinized Staphylococcus  aureus,  Epstein-Barr virus (EBV), and PWM,  will 
induce the expression of this antigen. 
In a preliminary experiment, a 58,000  (58 K) mol wt polypeptide was specifi- 
cally precipitated by antibody AB 1. Thus, this antigen is tentatively identified as 
a  58  K  mol  wt polypeptide.  A  number  of B  blast-specific  antigens  have  been JUNG  AND  FU  BRIEF  DEFINITIVE  REPORT  1923 
described. The mAb BB-1  identified a 37 K mol wt protein that was present on 
B cells activated by EBV and PWM stimulation (4). This antigen was also found 
on EBV-transformed B cell lines and leukemia B cells, and was similar in tissue 
distribution to B-LAST  1 (5)  and B532  (6),  although the latter antigens have 
molecular weights  of 45  K  with  no  apparent  cross-reactivity (13).  Recently, 
Posnett et al. (7) described a B cell activation antigen, HC-2. This mAb identified 
a  molecule of four peptides with molecular weights varying from 52  to 63  K. 
Relatively little data are available on the functional significance of these B blast- 
specific antigens. The cell distribution pattern and molecular weight suggest that 
the antigen detected by AB1 is distinct from these other B cell activation antigens. 
AB 1 was shown to specifically inhibit B cell proliferation that is dependent on 
CM-BSF.  In two B cell proliferation systems, independent of growth factors or 
T  cells,  and  in  four  T  cell  proliferation  systems,  AB1  had  no  appreciative 
inhibitory effect. Both  the supernatant and  IgG  of hybridoma AB1  behaved 
similarly. These results indicate that the inhibitory effect on CM-BSF-dependent 
B cell proliferation is probably not due to a nonspecific mechanism. 
A  number of factors are involved in the process of B cell proliferation. IL-1 
and  BSF  are active in  early B  cell proliferation  (14,  15),  while  IL-2  may be 
involved in a late stage of this process (9,  16). The present study, which used a 
BSF preparation devoid of IL-2 and which demonstrates the early effect of AB1, 
rules out the possibility that the AB1  inhibitory effect is caused by interference 
of the interaction between activated B cells and IL-2. IL-1 has been shown to be 
involved in T  cell proliferation induced by mitogens. Since we find that AB1 did 
not  inhibit  mitogen-induced  T  cell  proliferation,  it  is  unlikely  that  IL-1  is 
involved.  Thus,  ABl-induced  inhibition  of growth  factor-dependent  B  cell 
proliferation is probably caused by AB1  interfering with the binding of BSF to 
its  receptor.  This  raises  the  possibility  that  AB1  identifies  the  putative  BSF 
receptor. The finding that anti-IgM-activated B cells express antigen AB1 lends 
support to this possibility.  Further studies on the interaction between purified 
BSF and isolated AB 1 antigen are needed. 
Summary 
A monoclonal antibody, AB1, was established with activated human B cells as 
immunogen. AB1 stained activated B cells but not activated T  cells. Its selective 
reactivity to activated B  cells was further documented by its  nonreactivity to 
activated T  cells, resting T  and B cells, monocytes, granulocytes, bone marrow 
cells, leukemic cells, and cells from cell lines of T, B, and myeloid lineages. Upon 
activation, the antigen appeared on B cells as early as 3-4 h  after stimulation 
and was fully expressed by 38 h. The expression of this antigen was not dependent 
on the presence of B cell stimulatory factor(s). Anti-IgM antibodies by themselves 
induced its expression. AB 1 inhibited B cell proliferation that was induced by a 
low dose anti-IgM antibody and conditioned medium containing B cell stimula- 
tory factor. It did not inhibit B cell proliferation induced by either high doses of 
anti-IgM antibodies or by formalinized Staphylococcus  aureus.  It also failed to 
inhibit T  cell mitogenesis. The possibility exists that this antigen is related to the 
receptor for B cell stimulatory factor. 1924  JUNG  AND  FU  BRIEF  DEFINITIVE REPORT 
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